ArticleBrain and behavior2025
The Association Between FT4/FT3 Ratio and Prognosis in Ischemic Stroke: A Retrospective Cohort Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Association Between FT4/FT3 Ratio and Prognosis in Ischemic Stroke: A Retrospective Cohort Study.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe FT4/FT3 ratio reflects thyroid hormone metabolism and has emerged as a prognostic marker in cardiovascular diseases. However, its role in ischemic stroke (IS) remains unclear. This study aimed to investigate the association between the FT4/FT3 ratio and 3-month functional outcomes in IS patients.
methodsWe conducted a retrospective cohort study of 199 first-episode IS patients admitted within 14 days of onset between June 2021 and June 2023. Serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) were evaluated upon admission. Neurological severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) at admission. Functional outcomes were evaluated using the modified Rankin Scale (mRS) at 3 months post-stroke. Poor outcome was defined as an mRS score of 3-5. Separate analyses were conducted according to FT4/FT3 ratio and outcome.
resultsPatients were stratified by median FT4/FT3 ratio (3.75) into low (≤ 3.75, n = 100) and high (> 3.75, n = 99) ratio groups. The high-ratio group had lower FT3 (4.14 ± 0.52 vs. 4.68 ± 0.52 pg/mL, p < 0.001), higher FT4 (17.83 ± 2.10 vs. 15.36 ± 1.69 pmol/L, p < 0.001), more diabetes (52.5% vs. 34%, p = 0.010), and higher proportion of poor outcomes (46.5% vs. 28%, p = 0.007). Receiver operating characteristic (ROC) analysis revealed that the FT4/FT3 ratio demonstrated the highest predictive ability (area under the curve [AUC] = 0.662) with an optimal cut-off of 3.845. After adjusting for NIHSS scores, age, sex, and vascular risks, the FT4/FT3 ratio remained an independent predictor of poor outcomes (odds ratio [OR] = 2.589, 95% confidence interval [CI]: 1.171 - 5.727, p = 0.019). FT4 was a risk factor (OR = 1.324, 95% CI: 1.045 - 1.678, p = 0.020), while FT3 showed a nonsignificant protective trend (OR = 0.551, 95% CI: 0.218 - 1.390, p = 0.207).
conclusionAn elevated FT4/FT3 ratio may serve as a novel biomarker for predicting poor outcomes in ischemic stroke, reflecting thyroid hormone metabolic dysfunction that potentially exacerbates inflammation and impairs neuronal repair. LIMITATIONS: This study is limited by its small sample size, single-center design, and absence of serial hormone measurements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.